Publication: Effect of lymphadenectomy on survival in early-stage type II endometrial carcinoma and carcinosarcoma
| dc.contributor.coauthor | Sözen, Hamdullah | |
| dc.contributor.coauthor | Ersoy, Gülçin Şahin | |
| dc.contributor.coauthor | Giray, Burak | |
| dc.contributor.coauthor | Topuz, Samet | |
| dc.contributor.coauthor | İyibozkurt, A. Cem | |
| dc.contributor.coauthor | Salihoğlu, Yavuz | |
| dc.contributor.department | School of Medicine | |
| dc.contributor.kuauthor | Vatansever, Doğan | |
| dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
| dc.date.accessioned | 2024-11-09T11:37:08Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Purpose: we aimed to investigate whether systematic pelvic and paraaortic lymph node dissection delivers any survival advantage in a subgroup of patients with type II endometrial carcinoma and carcinosarcoma. Methods: we evaluated 135 patients with clinically early-stage (Stage I-II) type II endometrial carcinoma and carcinosarcoma who underwent systematic pelvic and paraaortic lymph node dissection or who did not undergo any lymph node dissection. Results: overall survival (OS) and recurrence-free survivals (RFS) were significantly longer in the systematic lymph node dissection group (hazard ratio 0.28, 95% CI 0.13-0.62 p=0.002 for OS and hazard ratio 0.31, 95% CI 0.14-0.69 p=0.004 for RFS). Multivariate analysis showed that lymph node dissection, age, lymph node metastasis, and adjuvant therapy were independent prognostic variables of OS and RFS. Conclusions: systematic pelvic and paraaortic lymph node dissection independently and significantly prolongs the survival of patients with early-stage type II endometrial carcinoma and carcinosarcoma. | |
| dc.description.fulltext | YES | |
| dc.description.indexedby | WOS | |
| dc.description.indexedby | Scopus | |
| dc.description.indexedby | PubMed | |
| dc.description.openaccess | YES | |
| dc.description.publisherscope | International | |
| dc.description.sponsoredbyTubitakEu | N/A | |
| dc.description.sponsorship | N/A | |
| dc.description.version | Publisher version | |
| dc.description.volume | 2020 | |
| dc.identifier.doi | 10.1155/2020/1295613 | |
| dc.identifier.eissn | 1687-8469 | |
| dc.identifier.embargo | NO | |
| dc.identifier.filenameinventoryno | IR02181 | |
| dc.identifier.issn | 1687-8450 | |
| dc.identifier.quartile | Q2 | |
| dc.identifier.scopus | 2-s2.0-85084659220 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14288/68 | |
| dc.identifier.wos | 529234800001 | |
| dc.keywords | Lymph-node metastasis | |
| dc.keywords | Paraaortic Lymphadenectomy | |
| dc.keywords | Adjuvant chemotherapy | |
| dc.keywords | Cancer | |
| dc.keywords | Risk | |
| dc.keywords | Proposal | |
| dc.keywords | Impact | |
| dc.keywords | Trial | |
| dc.language.iso | eng | |
| dc.publisher | Hindawi | |
| dc.relation.grantno | NA | |
| dc.relation.ispartof | Journal of Oncology | |
| dc.relation.uri | http://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/8805 | |
| dc.subject | Oncology | |
| dc.title | Effect of lymphadenectomy on survival in early-stage type II endometrial carcinoma and carcinosarcoma | |
| dc.type | Journal Article | |
| dspace.entity.type | Publication | |
| local.contributor.kuauthor | Vatansever, Doğan | |
| local.publication.orgunit1 | SCHOOL OF MEDICINE | |
| local.publication.orgunit2 | School of Medicine | |
| person.familyName | Vatansever | |
| person.givenName | Doğan | |
| relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
| relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |
Files
Original bundle
1 - 1 of 1
